Adams D, Koike H, Slama M, et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019; 15 (7): 387–404.
Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy. JAMA. 2020; 324 (1): 79–89.
Falk RH, Alexander KM, Liao R, et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016; 68 (12): 1323–1341. MDMDPHD MD, MPH
Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019; 73 (22): 2872–2891.
McWilliams-Koeppen HP, Foster JS, Hackenbrack N, et al. Light chain amyloid fibrils cause metabolic dysfunction in human cardiomyocytes. PLoS One. 2015; 10 (9): e0137716.
Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015; 66 (21): 2451–2466.
González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017; 38 (24): 1895–1904.
Suhr OB, Anan I, Backman C, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med. 2008; 263 (3): 294–301.
Habib G, Bucciarelli-Ducci C, Caforio ALP, et al. Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document in collaboration with the “working group on myocardial and pericardial diseases” of the european society of cardiology endorsed by the Indian academy of echocardiography. Eur Heart J Cardiovasc Imaging. 2017; 18 (10): 1090–1121.
Ogawa H, Mizuno Y, Ohkawara S, et al. Cardiac amyloidosis presenting as microvascular angina. Angiology. 2001; 52 (4): 273–278.
Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009; 120 (13): 1203–1212.
Falk RH, Quarta CC. Echocardiography in cardiac amyloidosis. Heart Fail Rev. 2015; 20 (2): 125–131.
Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis CLINICAL PERSPECTIVE. Circulation. 2015; 132 (16): 1570–1579.
Dungu JN, Valencia O, Pinney JH, et al. CMR-Based differentiation of AL and ATTR cardiac amyloidosis. JACC: Cardiovascular Imaging. 2014; 7 (2): 133–142.
Fontana M, Chung R, Hawkins PN, et al. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev. 2015; 20 (2): 133–144.
Dorbala S, Bokhari S, Miller E, et al. ASNC Practice points: 99mTechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. Released February 27 ; 2019.
Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. Cardiovascul Imag. 2011; 4 (6): 659–670.
Ramaekers J, Janssens J, Waumans L, et al. Indications and diagnostic yield of endomyocardial biopsies for unexplained cardiomyopathy, a single center experience. Acta Cardiologica. 2020; 75 (2): 138–146.
Ritts AJ, Cornell RF, Swiger K, et al. Current concepts of cardiac amyloidosis. Heart Fail Clin. 2017; 13 (2): 409–416.
Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatmentCleveland. Cleve Clin J Med. 2017; 84 (12 suppl 3): 12–26.
Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981; 63 (6): 1285–1288.
Tan NY, Mohsin Y, Hodge DO, et al. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2016; 27 (10): 1167–1173.
Itzhaki Ben Zadok O, Kornowski R. Cardiac care of patients with cardiac amyloidosis. Acta Haematol. 2020; 143 (4): 343–349.
Donnellan E, Wazni O, Saliba W, et al. Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation and mortality. J Cardiovasc Electrophysiol. 2019; 30 (11): 2427–2432.
Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace. 2015; 36 (41): 2793–2867. euv319.
Jimenez-Zepeda VH, Duggan P, Neri P, et al. Bortezomib-containing regimens for the treatment of newly diagnosed and relapsed amyloid light chain amyloidosis: a single-center experience. Clin Lymphoma Myeloma Leuk. 2016; 16 (6): e79–e84.
Sousa M, Monohan G, Rajagopalan N, et al. Heart transplantation in cardiac amyloidosis. Heart Fail Rev. 2017; 22 (3): 317–327.
Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018; 379 (1): 22–31.
Solomon SD, Adams D, Kristen A, et al. Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary Transthyretin-Mediated amyloidosis. Circulation. 2019; 139 (4): 431–443.
Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012; 19 (sup1): 34–36.
Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012; 101 (10): 805–813.
Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018; 379 (11): 1007–1016.
Thibaud D, Pablo Garcia P, Mazen H, et al. Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2020; 23 (2): 277–285.
